Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.42 |
| ▸ | DRD3 | P35462 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 4/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.37 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.37 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.37 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10698716 | 0.85 | MAPT (0.44) | LMNADRD2DRD3MAPTSMN1; SMN2 | |
| SCHEMBL9836780 | 0.80 | LMNA (0.49) | LMNADRD2DRD3 | |
| SCHEMBL9834554 | 0.80 | LMNA (0.49) | LMNADRD2DRD3 | |
| SCHEMBL9834088 | 0.80 | LMNA (0.49) | LMNADRD2DRD3 | |
| SCHEMBL10698993 | 0.80 | ALDH1A1 (0.46) | LMNASMN1; SMN2KDM4EGAAALDH1A1 | |
| SCHEMBL10698984 | 0.80 | ALDH1A1 (0.46) | LMNASMN1; SMN2KDM4EGAAALDH1A1 | |
| Hydrochloric Acid SCHEMBL9836442 | 0.79 | LMNA (0.48) | LMNADRD2DRD3 | |
| SCHEMBL23730026 | 0.76 | RAB9A (0.46) | LMNAMAPTSMN1; SMN2TDP1RAB9A | |
| SCHEMBL2657694 | 0.74 | RAB9A (0.41) | LMNAMAPTSMN1; SMN2TDP1RAB9A | |
| SCHEMBL10762717 | 0.74 | HSD17B10 (0.42) | LMNADRD2DRD3MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7776833-B2 | Use of cyclic bioisosters of purine system derivatives for treating diseases produced by disorders of niterergic and dopaminergic systems | Zhilov, Valery Khazhmuratovich (RU) | 2010-08-17 | — | — | US | disclosed |
| EP-2074998-A2 | Use of cyclic bioisosteres of purine system derivatives for the treatment of diseases caused by disorders of nitrergic and dopaminergic systems | Zhilov, Valery Khazhmuratovich (RU) | 2009-07-01 | — | — | EP | disclosed |
| EP-1655028-B1 | USE OF CYCLIC BIOISOSTERES OF PURINE SYSTEM DERIVATIVES FOR THE TREATMENT OF DISEASES CAUSED BY DISORDERS OF NITRERGIC AND DOPAMINERGIC SYSTEMS | ZHILOV VALERY KHAZHMURATOVICH (RU) | 2009-05-13 | — | — | EP | disclosed |
| US-20070135636-A1 | Use of cyclic bioisosters of purine system derivatives for treating diseases produced by disorders of niterergic and dopaminergic systems | VALERY KHAZHMURATOVICH ZHILOV (RU) | 2007-06-14 | — | — | US | disclosed |
| EP-1655028-A2 | USE OF CYCLIC BIOISOSTERES OF PURINE SYSTEM DERIVATIVES FOR THE TREATMENT OF DISEASES CAUSED BY DISORDERS OF NITRERGIC AND DOPAMINERGIC SYSTEMS | Zhilov, Valery Khazhmuratovich (RU) | 2006-05-10 | — | — | EP | disclosed |
| EP-0234011-B1 | 4-(1,2,5,6-TETRAHYDRO-1-ALKYL-3-PYRIDINYL)-2-THIAZOLAMINES AND 4-(HEXAHYDRO-1-ALKYL-3-PYRIDINYL)-2-THIAZOLAMINES | WARNER-LAMBERT COMPANY (US) | 1991-09-18 | — | — | EP | disclosed |
| EP-0234011-B1 | 4-(1,2,5,6-TETRAHYDRO-1-ALKYL-3-PYRIDINYL)-2-THIAZOLAMINES AND 4-(HEXAHYDRO-1-ALKYL-3-PYRIDINYL)-2-THIAZOLAMINES | WARNER-LAMBERT COMPANY (US) | 1991-09-18 | — | — | EP | disclosed |
| EP-0280873-A1 | Piperidines, medicines containing them and process for their preparation | Dr. Karl Thomae GmbH (DE) | 1988-09-07 | — | — | EP | disclosed |
| US-4739067-A | NERVOUS SYSTEM, PSYCHOLOGICAL DISORDERS, HYPOTENSIVE AGENT, HORMONE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1988-04-19 | — | — | US | disclosed |
| US-4739067-A | NERVOUS SYSTEM, PSYCHOLOGICAL DISORDERS, HYPOTENSIVE AGENT, HORMONE INHIBITORS | WARNER-LAMBERT COMPANY (US) | 1988-04-19 | — | — | US | disclosed |
| EP-0234011-A1 | 4-(1,2,5,6-tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines and 4-(hexahydro-1-alkyl-3-pyridinyl)-2-thiazolamines | WARNER-LAMBERT COMPANY (US) | 1987-09-02 | — | — | EP | disclosed |
| EP-0234011-A1 | 4-(1,2,5,6-tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines and 4-(hexahydro-1-alkyl-3-pyridinyl)-2-thiazolamines | WARNER-LAMBERT COMPANY (US) | 1987-09-02 | — | — | EP | disclosed |
| US-4650805-A | 4-(1,2,5,6-Tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines and 4-(hexahydro-1-alkyl-3-pyridinyl)-2-thiazolamines having anti-psychotic activity | WARNER-LAMBERT COMPANY (US) | 1987-03-17 | — | — | US | disclosed |
| US-4650805-A | 4-(1,2,5,6-Tetrahydro-1-alkyl-3-pyridinyl)-2-thiazolamines and 4-(hexahydro-1-alkyl-3-pyridinyl)-2-thiazolamines having anti-psychotic activity | WARNER-LAMBERT COMPANY (US) | 1987-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070135636-A1 | Use of cyclic bioisosters of purine system derivatives for treating diseases produced by disorders of niterergic and dopaminergic systems | ADORA2A, ADORA3, ADORA1 | LMNA 3490/4885DRD2 47/4885DRD3 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.